CTMX 10-KMar 16 '26
“• a one-time milestone payment of $5.0 million to ImmunoGen in prior year;”
VRDN 10-KFeb 26 '26
“We have an exclusive license to the worldwide rights to develop and commercialize veligrotug for all non-oncology indications that do not use radiopharmaceuticals, including the treatment of patients with TED, from ImmunoGen, Inc. ("ImmunoGen").”